Scilex Holding Company (NASDAQ:SCLX – Get Free Report)’s stock price traded down 8.3% during mid-day trading on Friday. The company traded as low as $1.4024 and last traded at $1.43. 58,942 shares were traded during mid-day trading, an increase of 49% from the average daily volume of 39,506 shares. The stock had previously closed at $1.56.
Analysts Set New Price Targets
Several research firms recently issued reports on SCLX. Wall Street Zen raised shares of Scilex from a “strong sell” rating to a “sell” rating in a report on Sunday, September 6th. Weiss Ratings lowered shares of Scilex from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, September 18th. One research analyst has rated the stock with a Sell rating. According to MarketBeat, the company has a consensus rating of “Sell”.
Read Our Latest Research Report on Scilex
Scilex Price Performance
The stock has a market capitalization of $12.14 million, a P/E ratio of -0.03 and a beta of 1.85. The company has a fifty day moving average of $3.40 and a two-hundred day moving average of $6.42.
Scilex (NASDAQ:SCLX – Get Free Report) last released its earnings results on Friday, August 14th. The company reported ($16.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($16.47). The business had revenue of $7.64 million during the quarter, compared to the consensus estimate of $16.00 million.
Institutional Investors Weigh In On Scilex
A hedge fund recently bought a new stake in Scilex stock. Marshall Wace LLP purchased a new position in Scilex Holding Company (NASDAQ:SCLX – Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 33,800 shares of the company’s stock, valued at approximately $150,000. Marshall Wace LLP owned about 0.40% of Scilex as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 69.67% of the company’s stock.
Scilex Company Profile
Scilex Holding Company is a biopharmaceutical company focused on developing and commercializing treatments for pain and related conditions. Its portfolio includes therapies designed to offer alternatives to conventional pain-management approaches. Its marketed products include ZTlido, a topical lidocaine system for pain associated with postherpetic neuralgia; Elyxyb, an oral celecoxib solution for acute migraine in adults; and GLOPERBA, an oral colchicine solution for preventing gout flares in adults.
Recommended Stories
- Five stocks we like better than Scilex
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Scilex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scilex and related companies with MarketBeat.com's FREE daily email newsletter.
